RIZATRIPTAN BENZOATE (rizatriptan benzoate) by Molecular Devices is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache (), migraine. First approved in 2013.
Drug data last refreshed 18h ago
5-HT 1B/1D receptors. MAXALT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Worked on RIZATRIPTAN BENZOATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.